August 3, 2021
August 3, 2021
SINGAPORE – August 03, 2021 – Lion TCR is pleased to announce that Scientific Founder & Chairman, Professor Antonio Bertoletti has been appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre (SDCT).
SDCT, established in September 2020, is an integrated centre that provides Cell, Tissue and Gene Therapy (CTGT) research and education as well as clinical trials and services. Bringing together the strengths and expertise of healthcare professionals from various clinical specialties of SingHealth hospitals and national specialty centres, the Centre aims to enhance patient care by improving diagnostics, therapeutics, research and health outcomes.
The Centre will also focus on formulating and coordinating cluster-wide Research and Development (R&D) activities pertaining to the development of novel CTGT products and associated technologies. SDCT will work with the Advanced Cell Therapy Research Institute, Singapore (ACTRIS) & Regenerative Medicine Institute of Singapore (REMEDIS). and closely coordinate efforts with Health Sciences Authority (HSA) and international stakeholders to establish Singapore as the hub of CTGT for the region.
As a Cellular Immunotherapy Infectious Diseases Lead, Professor Antonio will be
a) Overseeing translational work and/or clinical trials and real-world patient treatment in Cellular Immunotherapy in infectious diseases;
b) Participating and facilitating local and international Cellular Immunotherapy conferences, seminars and workshops organized by SDCT;
c) Participating in and facilitating Cellular Immunotherapy-related grants involving SDCT; and
d) Overseeing database for infectious diseases cellular immunotherapy trials and real-world patients.
For more information: https://www.singhealth.com.sg/patient-care/specialties-services/cell-therapy-centre
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient